Back

Immune-epicardial adiposity, associated with coronary artery disease, is modulated by semaglutide

30 August 2026 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Mechanisms of arrhythmias and gender differences Coronary Artery Disease ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Jose Ramon Gonzalez Juanatey

University Hospital of Santiago de Compostela, Santiago de Compostela (Spain)

7 More presentations in this session

Presentation thumbnail
Mexiletine in drug-refractory ventricular arrhythmias: real-world effectiveness and tolerability
Doctor H. Santos Moreira (Porto, PT)
Abstract Slides
Presentation thumbnail
Accelerated biological aging increases the 10-year mortality risk in patients with coronary artery disease after percutaneous coronary intervention
Doctor M. Liu (Beijing, CN)
Abstract Slides
Presentation thumbnail
Mortality and device intervention in patients with a history of atrial fibrillation: a substudy of APPRAISE ATP
Professor G. Boriani (Modena, IT)
Abstract Slides
Presentation thumbnail
Sex differences in long-term arrhythmogenic and mortality outcomes in patients with hypertrophic cardiomyopathy: a 20-year longitudinal observational study
Doctor D. Silva (Rochester, US)
Abstract Slides
Presentation thumbnail
From systemic adiposity to local epicardial adipose tissue targets: uncovering novel mechanisms and biomarkers in atrial fibrillation
Mr S. Huang (Beijing, CN)
Abstract Slides

Access the full session

Session thumbnail
Mechanisms of arrhythmias and gender differences

The Event

Event poster

ESC Congress 2026

30 August 2026 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Semaglutide effects on human epicardial and subcutaneous fat released exosomes, aortic endothelial cells and neutrophils
28 August 2023
thumbnail
Congress Presentation
Epicardial adipose tissue thickness - a new predictive factor for coronary artery disease
11 December 2024
thumbnail
Congress Presentation
Secretomes from human epicardial adipocytes modulate atrial lymphatics and atrial fibrosis
30 August 2024
thumbnail
Congress Presentation
Effects of once-weekly semaglutide on coronary outcomes in patients with type 2 diabetes mellitus with or at high risk for cardiovascular disease: insights from the SUSTAIN-6 trial
7 April 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources